Edesa Biotech's ARDS Drug Inhibits Inflammation from Influenza and Other Pathogens
Portfolio Pulse from Benzinga Newsdesk
Edesa Biotech, Inc. (NASDAQ:EDSA) announced positive findings from an in vitro study of its monoclonal antibody candidate, paridiprubart, against a panel of respiratory pathogens. The study was completed by the University of Toronto in parallel to the company's ongoing clinical study of EB05 (paridiprubart) in hospitalized Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS).
June 28, 2023 | 11:57 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Edesa Biotech's positive findings from its in vitro study of paridiprubart could potentially boost the company's stock in the short term as it indicates progress in their ongoing clinical study.
Positive results from clinical studies often lead to increased investor confidence, which can drive up the stock price. The fact that the study was conducted in parallel to an ongoing clinical study of the same drug in hospitalized Covid-19 patients further increases its relevance.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100